Welcome to our dedicated page for Bio-Path Hldgs news (Ticker: BPTH), a resource for investors and traders seeking the latest updates and insights on Bio-Path Hldgs stock.
Bio-Path Holdings Inc. (NASDAQ: BPTH) is a pioneering biotechnology company focused on developing innovative therapeutic products through its proprietary DNAbilize® technology. This technology enables the delivery of nucleic acid drugs throughout the human body via simple intravenous infusion. Bio-Path's primary focus is on oncology, aiming to provide effective treatments for various forms of cancer.
The company's lead product candidate, prexigebersen (BP1001), is currently in Phase II clinical trials for Acute Myeloid Leukemia (AML) in combination with low-dose cytarabine (LDAC) and decitabine. Additionally, Bio-Path is exploring prexigebersen's potential in combination with dasatinib for patients with blast-phase and accelerated-phase Chronic Myeloid Leukemia (CML).
Another key candidate, BP1002, targets the Bcl-2 protein, which plays a crucial role in cell survival for many cancers. BP1002 is being evaluated for its effectiveness against lymphoma and solid tumors, offering hope for venetoclax-resistant AML patients. The company's technological advantage lies in its DNAbilize® platform, a liposomal antisense DNA method that significantly improves oligonucleotide therapeutics' delivery and efficacy.
Bio-Path Holdings continues to expand its pipeline with additional candidates such as BP1003, a STAT3 antisense oligodeoxynucleotide, and BP1001-A, a modification designed for solid tumors. These developments emphasize the company's commitment to addressing unmet medical needs in oncology.
Recently, Bio-Path has made significant strides in its clinical programs, receiving positive feedback from the U.S. FDA and advancing its trials at renowned institutions including Weill Cornell Medical College and The University of Texas MD Anderson Cancer Center. The company maintains a robust intellectual property portfolio to protect its innovative DNAbilize® platform.
For investors and stakeholders, Bio-Path Holdings represents a forward-thinking entity with a strategic focus on developing novel RNAi nanoparticle drugs. The company's advancements in the clinical and preclinical stages underline its potential to make substantial contributions to cancer treatment paradigms.
Bio-Path Holdings (NASDAQ:BPTH) has announced a $4.0 million private placement priced at-the-market under Nasdaq rules. The company will issue and sell 4,597,702 shares of common stock (or equivalents), along with series A and B warrants to purchase additional shares. The purchase price is set at $0.87 per share, with warrants exercisable at $1.00 per share. The offering is expected to close around October 10, 2024.
H.C. Wainwright & Co. is acting as the exclusive placement agent. Bio-Path intends to use the net proceeds for working capital and general corporate purposes. The securities are being offered under Section 4(a)(2) of the Securities Act and have not been registered. The company has agreed to file a resale registration statement for these securities.
Bio-Path Holdings (NASDAQ:BPTH) has announced two significant developments:
1. Initiation of a therapeutic program to develop BP1001-A for treating obesity and related metabolic diseases, marking the first non-cancer application of their DNAbilize® technology.
2. Completion of enrollment in the third dosing cohort of the ongoing Phase 1/1b clinical trial evaluating BP1002 for refractory/relapsed acute myeloid leukemia (AML) patients, including venetoclax-resistant patients.
The company expects to begin preclinical studies for BP1001-A in Q4 2024, targeting insulin resistance. The rapid enrollment in the BP1002 trial highlights the urgent need for new treatment options in AML.
Bio-Path Holdings (NASDAQ:BPTH) announced a publication in Biomedicines highlighting the therapeutic potential of BP1003 in various cancer types. The article, titled 'BP1003 Decreases STAT3 Expression and Its Pro-Tumorigenic Functions in Solid Tumors and the Tumor Microenvironment,' describes the broad anti-tumor effect of BP1003 in preclinical solid tumor models including breast, ovarian, and pancreatic cancer.
BP1003 is a neutral liposome incorporated with a nuclease resistant P-ethoxy antisense oligodeoxynucleotide targeting the STAT3 mRNA. The company believes BP1003 has the potential to enhance the efficacy of current standard of care chemotherapies in a broad range of difficult to treat cancers. This publication marks Bio-Path's twenty-second peer-reviewed article supporting its DNAbilize® technology.
Stonegate Capital Partners has updated its coverage on Bio-Path Holdings, Inc. (NASDAQ: BPTH) for the second quarter of 2024. This update provides investors with fresh insights into the company's performance and market position. Bio-Path Holdings is a biotechnology company focused on developing innovative therapies using its proprietary DNAbilize® antisense RNAi nanoparticle technology. The update from Stonegate Capital Partners, a respected financial research firm, is likely to offer valuable analysis on Bio-Path's recent developments, financial health, and future prospects in the competitive biotech sector.
Bio-Path Holdings (NASDAQ:BPTH) announced that CEO Peter Nielsen will give a pre-recorded presentation at the H.C. Wainwright 26th Annual Global Investment Conference on September 9, 2024, at 7:00 a.m. ET. The presentation will be available via audio webcast on the company's website for approximately 90 days.
Bio-Path is developing DNAbilize®, a novel RNAi nanoparticle drug delivery technology. Their pipeline includes:
- Prexigebersen (BP1001): In Phase 2 for blood cancers
- BP1001-A: In Phase 1/1b for solid tumors
- BP1002: Targeting Bcl-2 protein for blood cancers and solid tumors
- BP1003: STAT3 inhibitor with upcoming IND application
The company's technology allows for simple intravenous infusion of their targeted nucleic acid cancer drugs.
Bio-Path Holdings (NASDAQ:BPTH) reports positive outcomes from its ongoing clinical trials. In the Phase 1/1b trial of BP1001-A for solid tumors, the first patient treated with a higher dose (90 mg/m2) showed tumor regression and stable disease. This elderly female patient with gynecologic cancer experienced a 15% reduction in her primary tumor through six cycles of treatment, after failing multiple lines of chemotherapy and surgeries.
Additionally, two elderly patients in the Phase 2 triple combination study of prexigebersen for Acute Myeloid Leukemia (AML) demonstrated extended treatment durability. One patient has received 16 cycles over 21 months, while another has completed 12 cycles over 14 months, both remaining in complete remission.
These results support the potential of Bio-Path's DNAbilize® platform technology to treat vulnerable cancer patients with fewer side effects compared to standard therapies.
Bio-Path Holdings (NASDAQ:BPTH) reported its Q2 2024 financial results and corporate updates. Key highlights include:
Financial Results:
- Net loss of $1.9 million ($1.16 per share) vs $4.2 million ($10.64 per share) in Q2 2023
- R&D expenses decreased to $1.9 million from $3.1 million in Q2 2023
- G&A expenses remained stable at $1.2 million
- Cash position of $4.0 million as of June 30, 2024
Corporate Developments:
- Presented interim results from Phase 2 study of prexigebersen at ASCO and EHA
- Closed $4.0 million private placement in June
- Advancing clinical programs for blood cancers and solid tumors
Bio-Path Holdings (NASDAQ: BPTH) has announced it will host a live conference call and audio webcast on August 15, 2024 at 8:30 a.m. ET to report financial results for the second quarter ended June 30, 2024 and provide a business overview. The company is developing DNAbilize®, a novel RNAi nanoparticle drug technology administered via intravenous transfusion.
Bio-Path's pipeline includes prexigebersen (BP1001) in Phase 2 for blood cancers, BP1001-A in Phase 1/1b for solid tumors, and BP1002 targeting Bcl-2 protein for blood cancers and solid tumors. An IND is expected for BP1003, a STAT3 inhibitor.
Bio-Path Holdings (NASDAQ:BPTH), a biotechnology firm, has provided an update on its clinical programs and expansion plans. The company has made significant progress across multiple cancer studies and has completed the development of oncology molecular biomarkers. Additionally, Bio-Path is preparing preclinical studies for prexigebersen as a potential obesity treatment. The company's clinical development program includes one Phase 2 trial and three Phase 1/1b trials. Key updates include: advancing to the second dose level in a Phase 1/1b trial for BP1001-A, completing the second dose cohort in a Phase 1/1b trial for BP1002, and ongoing enrollment in a Phase 1 trial for BP1002 in refractory/relapsed lymphoma and CLL. Bio-Path has also announced preclinical work for BP1003 targeting STAT3 protein and the potential of prexigebersen for obesity-related cancers. The company’s DNAbilize® platform continues to show promise across multiple indications.
Bio-Path Holdings presented interim results from its Phase 2 study of prexigebersen (BP1001) in combination with decitabine and venetoclax for treating acute myeloid leukemia (AML) at the 2024 European Hematology Association Congress.
Dr. Jorge Cortes presented data showing the combination therapy was well-tolerated and demonstrated significant clinical improvements. In Cohort 1, 75% of evaluable newly diagnosed AML patients achieved complete remission (CR), CR with partial recovery (CRh), or CR with incomplete hematologic recovery (CRi). In Cohort 2, 55% of evaluable relapsed/refractory AML patients achieved CR/CRi/CRh. Adverse events included fatigue, anemia, and neutropenia, with severe events like febrile neutropenia and sepsis. Bio-Path plans to continue enrolling up to 98 and 54 patients for Cohorts 1 and 2 respectively.
FAQ
What is the current stock price of Bio-Path Hldgs (BPTH)?
What is the market cap of Bio-Path Hldgs (BPTH)?
What is Bio-Path Holdings Inc. known for?
What is DNAbilize® technology?
What is prexigebersen (BP1001)?
What is BP1002 and what does it target?
Which institutions are involved in Bio-Path's clinical trials?
What is the potential advantage of BP1002 over current treatments?
What are the main benefits of DNAbilize® technology for patients?
What is BP1003 and what does it target?
How does Bio-Path Holdings protect its innovations?
How can investors get more information about Bio-Path Holdings?
